Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
abrdn Life Sciences Investors's revenue per share for the
six
months ended in Mar. 2026 was $2.16.
abrdn Life Sciences Investors's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $6.13.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for abrdn Life Sciences Investors's Revenue per Share or its related term are showing as below:
During the past 9 years, abrdn Life Sciences Investors's highest 3-Year average Revenue Per Share Growth Rate was 28.40% per year. The lowest was -45.70% per year. And the median was 4.50% per year.
HQL's 3-Year Revenue Growth Rate is not ranked *
in the Asset Management industry.
Industry Median: 7.8 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
abrdn Life Sciences Investors Revenue per Share Related Terms
abrdn Life Sciences Investors Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors Revenue per Share Chart
HQL vs IIM, NOAH, FAX: Revenue per Share Comparison
For the Asset Management subindustry, abrdn Life Sciences Investors's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
abrdn Life Sciences Investors PS Ratio vs Asset Management Industry
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's PS Ratio distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's PS Ratio falls into.
abrdn Life Sciences Investors Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $6.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors (HQL) has a Revenue per Share of $6.13 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on abrdn Life Sciences Investors and its competitors. According to the industry distribution chart, abrdn Life Sciences Investors ranks #999999 out of 902 companies in the Asset Management industry.
Is abrdn Life Sciences Investors' Revenue per Share too high?
abrdn Life Sciences Investors' current Revenue per Share is $6.13. The Asset Management industry median Revenue per Share is 7.80. abrdn Life Sciences Investors' value of $6.13 is 21.4% below this industry median. Based on the distribution chart, abrdn Life Sciences Investors ranks #999999 out of 902 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' Revenue per Share compare to IIM and NOAH?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #999999 out of 902 companies for Revenue per Share. This places abrdn Life Sciences Investors in the lower half of its industry. The industry median Revenue per Share is 7.80. abrdn Life Sciences Investors' value of $6.13 is 21.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for an Asset Management company?
The median Revenue per Share among Asset Management companies is 7.80, based on 902 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. abrdn Life Sciences Investors's current Revenue per Share of $6.13 is 21.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on abrdn Life Sciences Investors and its competitors. For the Asset Management industry, the median Revenue per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current Revenue per Share is $6.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.21 — trading 64.2% below its estimated fair value. The current Revenue per Share is $6.13 and 21.4% below the Asset Management industry median of 7.80. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current Revenue per Share is $6.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?
Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued.
The current stock price of $22.21 is trading 64.2% below its estimated GF Value™ of $62.01.
GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.
Key valuation signals for HQL:
Revenue per Share: $6.13
GF Value™: $62.01 vs. price of $22.21 (64.2% below fair value)
Industry Position: 21.4% below the Asset Management median (#999999 of 902)
No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score
Get the complete analysis for HQL
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HQL has been successfully added to your 
